Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

407.83 +17.81 (+4.57%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

69 70 Next >

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial ↗

July 31, 2025

Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.

Via Benzinga

2 Top Dividend Stocks to Buy Right Now and Hold Forever ↗

July 28, 2025

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.

Via The Motley Fool

Topics Intellectual Property

1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

July 25, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

What Analysts Are Saying About Amgen Stock ↗

July 21, 2025

Via Benzinga

This Is What Whales Are Betting On Amgen ↗

July 21, 2025

Via Benzinga

What Does the Market Think About Amgen? ↗

July 11, 2025

Via Benzinga

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate ↗

July 24, 2025

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.

Via Benzinga

2 Reasons to Like AMGN and 1 to Stay Skeptical

July 24, 2025

Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up...

Via StockStory

Topics Government Stocks

Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest

July 16, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the...

Via StockStory

Topics Artificial Intelligence

July 15, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

How Does Nvidia's Reaching $4 Trillion in Market Cap Impact the S&P 500, Nasdaq-100, and Dow Jones? ↗

July 14, 2025

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?' ↗

July 10, 2025

Via Benzinga

Topics Economy Government

This House of Representative Just Bought Up To $30K In Amgen Stock ↗

July 10, 2025

Via Benzinga

1 Top Dividend Growth Stock to Buy Right Now ↗

July 10, 2025

Via The Motley Fool

Topics Intellectual Property

Better Dividend ETF to Buy for Passive Income: SCHD or GCOW ↗

July 03, 2025

Via The Motley Fool

Topics ETFs Stocks

Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades' ↗

July 03, 2025

Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets.

Via Benzinga

This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk ↗

July 01, 2025

Via The Motley Fool

Why Amgen Stock Popped by 4% Today ↗

July 01, 2025

Via The Motley Fool

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3% ↗

July 01, 2025

The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.

Via Benzinga

Topics Stocks

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects ↗

June 30, 2025

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.

Via Benzinga

Amgen’s Cancer Drug Improves Survival In Late-stage Trial ↗

June 30, 2025

Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in the trial.

Via Stocktwits

Topics Death

2 Dividend Stocks to Buy on the Dip and Hold Forever ↗

June 30, 2025

Via The Motley Fool

Topics Government Stocks World Trade

Where Amgen Stands With Analysts ↗

June 24, 2025

Via Benzinga

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues ↗

June 24, 2025

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Via Benzinga

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update ↗

June 23, 2025

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.

Via Benzinga

Uncover the latest developments among S&P500 stocks in today's session. ↗

June 23, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

Amgen Expands Development Plans For Highly Anticipated Obesity Drug ↗

June 23, 2025

Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.

Via Investor's Business Daily

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.